<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02018510</url>
  </required_header>
  <id_info>
    <org_study_id>MCA-0835</org_study_id>
    <nct_id>NCT02018510</nct_id>
  </id_info>
  <brief_title>A Phase 1, Open Label, Dose-escalation Study of the Safety, Pharmacokinetics and Antiretroviral Activity of 3BNC117</brief_title>
  <official_title>A Phase 1, Open Label, Dose-escalation Study of the Safety, Pharmacokinetics and Antiretroviral Activity of 3BNC117 Monoclonal Antibody in HIV-infected and HIV-uninfected Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rockefeller University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Cologne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rockefeller University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed study is a first-in-man phase I study that aims to evaluate the safety,
      tolerability and pharmacokinetics of 3BNC117 in HIV-infected and HIV-uninfected subjects, and
      its antiretroviral activity in HIV-infected subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In preclinical studies carried out in humanized mice and non-human primates, 3BNC117 alone or
      in combination with other neutralizing antibodies led to protection from HIV-1 or SHIV
      infection and also to sustained suppression of HIV-1 plasma viremia. The aims of this
      protocol are to evaluate the safety, tolerability and pharmacokinetics profile of 3BNC117 in
      both HIV-infected and HIV-uninfected subjects,and its antiretroviral activity in HIV-infected
      subjects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>24 weeks</time_frame>
    <description>To evaluate the safety and tolerability profile of one or two intravenous infusions of 3BNC117 at 3 increasing dose levels in HIV-infected and HIV-uninfected individuals.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profile</measure>
    <time_frame>24 hours post infusion</time_frame>
    <description>To determine the pharmacokinetic profile of one or two intravenous infusions of 3BNC117 in HIV-uninfected and HIV-infected subjects.</description>
  </secondary_outcome>
  <number_of_arms>15</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Healthy</condition>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>Group 1A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIV-uninfected individuals
1 mg/kg, single dose IV administration of 3BNC117</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Groups 1B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIV-uninfected individuals 3 mg/kg, single dose IV administration of 3BNC117</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIV-uninfected individuals 10 mg/kg, single dose IV administration of 3BNC117</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIV-uninfected individuals 10 mg/kg, two doses IV of 3BNC117</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIV-uninfected individuals 30 mg/kg, single dose IV administration of 3BNC117</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1F</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIV-uninfected individuals 30 mg/kg, two doses IV of 3BNC117</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIV-infected individuals on or off ART
1 mg/kg, single dose IV administration of 3BNC117</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIV-infected individuals on or off ART 3 mg/kg, single dose IV administration of 3BNC117</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIV-infected individuals on or off ART 10 mg/kg, single dose IV administration of 3BNC117</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIV-infected individuals on or off ART 30 mg/kg, single dose IV administration of 3BNC117</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIV-infected individuals off ART, VL 2,000-100,000 copies/ml 30 mg/kg, single dose IV administration of 3BNC117</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIV-infected individuals off ART, VL &lt; 2,000 copies/ml 30 mg/kg, single dose IV administration of 3BNC117</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIV-infected individuals on ART, VL &lt; 100,000 copies/ml 30 mg/kg, single dose IV administration of 3BNC117</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIV-infected individuals on ART, VL &lt; 20 copies/ml 10 mg/kg, single dose IV administration of 3BNC117</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIV-infected individuals on ART, VL &lt; 20 copies/ml 30 mg/kg, single dose IV administration of 3BNC117</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>1 mg/kg, single dose IV administration of 3BNC117</intervention_name>
    <description>1 mg/kg, single dose IV administration of 3BNC117</description>
    <arm_group_label>Group 1A</arm_group_label>
    <arm_group_label>Group 2A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>3 mg/kg, single dose IV administration of 3BNC117</intervention_name>
    <description>3 mg/kg, single dose IV administration of 3BNC117</description>
    <arm_group_label>Groups 1B</arm_group_label>
    <arm_group_label>Group 2B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>10 mg/kg, single dose IV administration of 3BNC117</intervention_name>
    <description>10 mg/kg, single dose IV administration of 3BNC117</description>
    <arm_group_label>Group 1C</arm_group_label>
    <arm_group_label>Group 2C</arm_group_label>
    <arm_group_label>Group 5A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>30 mg/kg, single dose IV administration of 3BNC117</intervention_name>
    <description>30 mg/kg, single dose IV administration of 3BNC117</description>
    <arm_group_label>Group 1E</arm_group_label>
    <arm_group_label>Group 2D</arm_group_label>
    <arm_group_label>Group 2E</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_label>Group 5B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>10 mg/kg, two doses IV of 3BNC117</intervention_name>
    <description>10 mg/kg, two IV administrations of 3BNC117 at weeks 0 and 12</description>
    <arm_group_label>Group 1D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>30 mg/kg, two doses IV of 3BNC117</intervention_name>
    <description>30 mg/kg, two IV administrations of 3BNC117 at weeks 0 and 12</description>
    <arm_group_label>Group 1F</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Group 1 (HIV-uninfected):

               -  Adult males and females, age 18 to 65

               -  Amenable to HIV risk reduction counseling and agrees to maintaining behavior
                  consistent with low risk of HIV exposure;

               -  If a sexually active male or female, participating in sexual activity that could
                  lead to pregnancy, agrees to use an effective method of contraception throughout
                  the study.

          -  Groups 2-5 (HIV-infected):

               -  Age 18 to 65

               -  HIV infection confirmed by ELISA and immunoblot

               -  Groups 2A-D - on ART with HIV-1 plasma RNA levels below 100,000 copies/ml, or off
                  ART for at least 8 weeks with HIV-1 plasma RNA level between 2,000-100,000
                  copies/ml by standard assays on 2 occasions at least 1 week apart;

               -  Group 2E - Untreated HIV-infected (not on ART for at least 8 weeks): HIV-1 RNA
                  plasma levels between 2,000 - 100,000 copies/ml;

               -  Group 3 - Untreated HIV controllers (not on ART for at least 8 weeks): HIV-1 RNA
                  plasma level of &lt; 2,000 copies/ml by standard assays, on 2 occasions, at least 1
                  week apart, and ART-naive.

               -  Group 4 - ART treated with HIV-1 RNA plasma level of &gt; 20 copies/ml by standard
                  assays on 2 occasions, at least 1 week apart, while on combination antiretroviral
                  therapy;

               -  Groups 5A and 5B - ART treated with HIV-1 RNA plasma level of &lt; 20 copies/ml by
                  standard assays on 2 occasions, at least 1 week apart, while on combination
                  antiretroviral therapy;

               -  Current CD4 cell count &gt; 300 cells/µl

               -  If sexually active male and female, participating in sexual activity that could
                  lead to pregnancy, agrees to use an effective method of contraception throughout
                  the study.

        Exclusion criteria:

          -  Group 1 (HIV-uninfected):

               -  Confirmed HIV-1 or HIV-2 infection;

               -  History of immunodeficiency or autoimmune disease; use of systemic
                  corticosteroids, immunosuppressive anti-cancer, or other medications considered
                  significant by the trial physician within the last 6 months;

               -  Any clinically significant acute or chronic medical condition that in the opinion
                  of the investigator would preclude participation;

               -  Within the 12 months prior to enrollment, the volunteer has a history of sexually
                  transmitted disease;

               -  Hepatitis B (surface antigen, HbsAg) or hepatitis C (HCV antibodies);

               -  Laboratory abnormalities in the parameters listed below:

                    -  Absolute neutrophil count ≤ 2,000

                    -  Hemoglobin ≤ 12 gm/dL if female; ≤ 13.5 gm/dL if male

                    -  Platelet count ≤ 140,000

                    -  ALT ≥ 1.25 x ULN

                    -  AST ≥ 1.25 x ULN

                    -  Total bilirubin ≥ 1.1 ULN

                    -  Creatinine ≥ 1.1 x ULN

                    -  Coagulation parameters (PT, PTT, INR) ≥ 1.1 x ULN

               -  Pregnancy or breastfeeding;

               -  Any vaccination within 14 days prior to 3BNC117 administration;

               -  Receipt of any experimental HIV vaccine in the past or monoclonal antibody
                  therapy of any kind in the past;

               -  Participation in another clinical study of an investigational product currently
                  or within past 12 weeks, or expected participation during this study.

          -  Groups 2-5 (HIV-infected):

               -  History of AIDS-defining illness

               -  History of systemic corticosteroids, immunosuppressive anti-cancer, or other
                  medications considered significant by the trial physician within the last 6
                  months;

               -  Any clinically significant acute or chronic medical condition, other than HIV
                  infection, that in the opinion of the investigator would preclude participation;

               -  Hepatitis B (surface antigen, HbsAg) or hepatitis C (HCV antibodies);

               -  Laboratory abnormalities in the parameters listed below:

                    -  Absolute neutrophil count ≤ 1,300

                    -  Hemoglobin ≤ 10 gm/dL

                    -  Platelet count ≤ 125,000

                    -  ALT ≥ 2.0 x ULN

                    -  AST ≥ 2.0 x ULN

                    -  Total bilirubin ≥ 1.1 ULN

                    -  Creatinine ≥ 1.1 x ULN

                    -  Coagulation parameters ≥ 1.1 x ULN;

               -  Current antiretroviral regimen includes either maraviroc or enfuvirtide;

               -  Pregnancy or breastfeeding;

               -  Any vaccination within 14 days prior to 3BNC117 administration;

               -  Receipt of any experimental HIV vaccine or monoclonal antibody therapy of any
                  kind in the past;

               -  Participation in another clinical study of an investigational product currently
                  or within past 12 weeks, or expected participation during this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marina Caskey, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rockefeller Univesrity</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Rockefeller University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cologne</name>
      <address>
        <city>Cologne</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 17, 2013</study_first_submitted>
  <study_first_submitted_qc>December 20, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2013</study_first_posted>
  <last_update_submitted>December 23, 2016</last_update_submitted>
  <last_update_submitted_qc>December 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy Volunteers</keyword>
  <keyword>HIV</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

